CY1113934T1 - Σχηματισμος αποξηραμενου αναγεννημενου κυστιδιου για φαρμακευτικη εφαρμογη - Google Patents
Σχηματισμος αποξηραμενου αναγεννημενου κυστιδιου για φαρμακευτικη εφαρμογηInfo
- Publication number
- CY1113934T1 CY1113934T1 CY20131100316T CY131100316T CY1113934T1 CY 1113934 T1 CY1113934 T1 CY 1113934T1 CY 20131100316 T CY20131100316 T CY 20131100316T CY 131100316 T CY131100316 T CY 131100316T CY 1113934 T1 CY1113934 T1 CY 1113934T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dried
- pharmaceutical application
- cylinder formation
- refrigerated cylinder
- drvs
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000008346 aqueous phase Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06021093 | 2006-10-06 | ||
| EP07818735A EP2081551B1 (en) | 2006-10-06 | 2007-10-05 | Dried reconstituted vesicle formation for pharmaceutical application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113934T1 true CY1113934T1 (el) | 2016-07-27 |
Family
ID=38910893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100316T CY1113934T1 (el) | 2006-10-06 | 2013-04-18 | Σχηματισμος αποξηραμενου αναγεννημενου κυστιδιου για φαρμακευτικη εφαρμογη |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9526761B2 (enExample) |
| EP (2) | EP2081551B1 (enExample) |
| JP (2) | JP5404402B2 (enExample) |
| KR (1) | KR101333279B1 (enExample) |
| CN (3) | CN101528197B (enExample) |
| CA (1) | CA2664637C (enExample) |
| CY (1) | CY1113934T1 (enExample) |
| DK (1) | DK2081551T3 (enExample) |
| ES (2) | ES2400162T3 (enExample) |
| HR (1) | HRP20130328T1 (enExample) |
| PL (1) | PL2081551T3 (enExample) |
| PT (1) | PT2081551E (enExample) |
| RS (1) | RS52706B (enExample) |
| RU (1) | RU2443412C2 (enExample) |
| SI (1) | SI2081551T1 (enExample) |
| TW (1) | TWI455731B (enExample) |
| WO (2) | WO2008040557A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258690B2 (en) | 2003-03-28 | 2007-08-21 | Relievant Medsystems, Inc. | Windowed thermal ablation probe |
| US6907884B2 (en) | 2002-09-30 | 2005-06-21 | Depay Acromed, Inc. | Method of straddling an intraosseous nerve |
| US8361067B2 (en) | 2002-09-30 | 2013-01-29 | Relievant Medsystems, Inc. | Methods of therapeutically heating a vertebral body to treat back pain |
| EP1868539A2 (en) | 2005-04-15 | 2007-12-26 | Musculoskeletal Transplant Foundation | Vertebral disc repair |
| US7959683B2 (en) | 2006-07-25 | 2011-06-14 | Musculoskeletal Transplant Foundation | Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation |
| CA2737374C (en) | 2008-09-26 | 2017-03-28 | Relievant Medsystems, Inc. | Systems and methods for navigating an instrument through bone |
| US10028753B2 (en) | 2008-09-26 | 2018-07-24 | Relievant Medsystems, Inc. | Spine treatment kits |
| WO2011103462A1 (en) | 2010-02-18 | 2011-08-25 | Osiris Therapeutics, Inc. | Methods of manufacture of immunocompatible amniotic membrane products |
| WO2011134979A2 (en) * | 2010-04-27 | 2011-11-03 | Scil Technology Gmbh | Stable mia/cd-rap formulation |
| US10390877B2 (en) | 2011-12-30 | 2019-08-27 | Relievant Medsystems, Inc. | Systems and methods for treating back pain |
| US20130202682A1 (en) * | 2012-01-24 | 2013-08-08 | The Trustees Of Columbia University In The City Of New York | Synthetic matrix vesicles for biomimetic mineralization |
| BR112015000174A2 (pt) * | 2012-07-05 | 2017-06-27 | Taiwan Liposome Co Ltd | método para o tratamento da artrite |
| US10588691B2 (en) | 2012-09-12 | 2020-03-17 | Relievant Medsystems, Inc. | Radiofrequency ablation of tissue within a vertebral body |
| IL238516B (en) | 2012-11-05 | 2022-08-01 | Relievant Medsystems Inc | System and methods for creating curved pathways through bone and regulating the nerves within the bone |
| US9724151B2 (en) | 2013-08-08 | 2017-08-08 | Relievant Medsystems, Inc. | Modulating nerves within bone using bone fasteners |
| US8986732B2 (en) | 2013-08-12 | 2015-03-24 | Helix Biopharma Corporation | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| US10159646B2 (en) * | 2013-08-12 | 2018-12-25 | Altum-Avro Pharma Partnership | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| ES2726924T3 (es) * | 2014-12-18 | 2019-10-10 | Bracco Suisse Sa | Formulación de microvesículas dirigidas rellenas de gas |
| AU2016256979B2 (en) | 2015-05-04 | 2021-01-28 | Genfit | Method for preparing transmembrane pH-gradient vesicles |
| WO2017046314A2 (en) * | 2015-09-18 | 2017-03-23 | Sanofi | Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein |
| WO2017176196A1 (en) * | 2016-04-04 | 2017-10-12 | Chalmers Ventures Ab | Methods and compositions for the treatment of intervertebral disc herniation |
| CN110582282A (zh) * | 2017-04-25 | 2019-12-17 | 佐剂技术公司 | 三萜皂苷类似物 |
| TWI806894B (zh) * | 2017-08-28 | 2023-07-01 | 台灣微脂體股份有限公司 | 緩釋麻醉劑組成物及其製備方法 |
| US11389405B2 (en) | 2017-09-18 | 2022-07-19 | North Carolina State University | Artificial beta cells and methods of use thereof |
| KR102649069B1 (ko) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물 |
| CN112261871B (zh) | 2018-07-28 | 2022-05-17 | 韩国外泌体生技有限公司 | 用于使外排体冻干的方法 |
| KR102163806B1 (ko) * | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| DK3864163T3 (da) * | 2018-10-09 | 2024-05-06 | Univ British Columbia | Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed |
| AU2020346827B2 (en) | 2019-09-12 | 2026-03-12 | Relievant Medsystems, Inc. | Systems and methods for tissue modulation |
| AU2021306313B2 (en) | 2020-07-10 | 2026-07-09 | Relievant Medsystems, Inc. | Vertebral denervation in conjunction with vertebral fusion |
| US12082876B1 (en) | 2020-09-28 | 2024-09-10 | Relievant Medsystems, Inc. | Introducer drill |
| AU2021409967A1 (en) | 2020-12-22 | 2023-08-03 | Relievant Medsystems, Inc. | Prediction of candidates for spinal neuromodulation |
| US12433668B1 (en) | 2021-11-08 | 2025-10-07 | Relievant Medsystems, Inc. | Impedance stoppage mitigation during radiofrequency tissue ablation procedures |
| CN113995852B (zh) * | 2021-11-08 | 2024-01-30 | 河北大学 | Arg-脂质体微囊、微囊包封的鱼精蛋白-siRNA复合体及其制备方法和应用 |
| CN221431621U (zh) * | 2023-07-10 | 2024-07-30 | 常州富谦生物科技有限公司 | 一种多层膜结构 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH621479A5 (enExample) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| FR2416008A1 (fr) * | 1978-02-02 | 1979-08-31 | Oreal | Lyophilisats de liposomes |
| IL79114A (en) * | 1985-08-07 | 1990-09-17 | Allergan Pharma | Method and composition for making liposomes |
| FR2591105B1 (fr) * | 1985-12-11 | 1989-03-24 | Moet Hennessy Rech | Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide. |
| US4897353A (en) * | 1986-03-13 | 1990-01-30 | University Of Southwestern Louisiana | Cryogenic protection of phosphofructokinase using amino acids and zinc ions |
| US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
| AU8329391A (en) * | 1990-08-08 | 1992-03-02 | Liposome Technology, Inc. | Stable doxorubicin/liposome composition |
| CA2120197A1 (en) * | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
| GB9320668D0 (en) | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| US6066331A (en) * | 1994-07-08 | 2000-05-23 | Barenholz; Yechezkel | Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers |
| IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| AU5702099A (en) * | 1998-09-01 | 2000-03-21 | Millennium Pharmaceuticals, Inc. | A novel protein related to melanoma-inhibiting protein and uses thereof |
| EP1025871A1 (en) * | 1999-01-28 | 2000-08-09 | F. Hoffmann-La Roche Ag | Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair |
| US7435260B2 (en) * | 1999-08-13 | 2008-10-14 | Ferree Bret A | Use of morphogenetic proteins to treat human disc disease |
| DK1244388T3 (da) * | 1999-12-06 | 2007-05-14 | Warsaw Orthopedic Inc | Indretning til behandling af mellemhvirvelskiver |
| EP1432403B1 (en) * | 2001-10-03 | 2010-07-28 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| CA2486967A1 (en) * | 2002-05-24 | 2003-12-04 | Neopharm, Inc. | Cardiolipin compositions their methods of preparation and use |
| US7169405B2 (en) * | 2003-08-06 | 2007-01-30 | Warsaw Orthopedic, Inc. | Methods and devices for the treatment of intervertebral discs |
| KR101153035B1 (ko) * | 2004-03-30 | 2012-06-11 | 리립사, 인크. | 이온 결합 조성물 |
| WO2005113032A2 (en) * | 2004-05-21 | 2005-12-01 | Synthes (U.S.A.) | Replacement of nucleus pulposus using a hydrogel |
| CA2567405A1 (en) * | 2004-05-25 | 2005-12-08 | Stryker Corporation | Use of morphogenic proteins for treating cartilage defects |
| EP1604693A1 (en) * | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | In situ forming scaffold, its manufacturing and use |
| CA2584583A1 (en) * | 2004-10-28 | 2006-05-11 | Alza Corporation | Lyophilized liposome formulations and method |
| US20110071056A1 (en) * | 2009-09-24 | 2011-03-24 | Rajesh K Saini | Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods |
-
2007
- 2007-10-05 PL PL07818735T patent/PL2081551T3/pl unknown
- 2007-10-05 WO PCT/EP2007/008660 patent/WO2008040557A1/en not_active Ceased
- 2007-10-05 JP JP2009530810A patent/JP5404402B2/ja not_active Expired - Fee Related
- 2007-10-05 HR HRP20130328TT patent/HRP20130328T1/hr unknown
- 2007-10-05 CN CN2007800397245A patent/CN101528197B/zh not_active Expired - Fee Related
- 2007-10-05 RS RS20130131A patent/RS52706B/sr unknown
- 2007-10-05 SI SI200731193T patent/SI2081551T1/sl unknown
- 2007-10-05 CN CNA2007800422016A patent/CN101605534A/zh active Pending
- 2007-10-05 KR KR1020097009193A patent/KR101333279B1/ko not_active Expired - Fee Related
- 2007-10-05 WO PCT/EP2007/008659 patent/WO2008040556A1/en not_active Ceased
- 2007-10-05 EP EP07818735A patent/EP2081551B1/en active Active
- 2007-10-05 ES ES07818735T patent/ES2400162T3/es active Active
- 2007-10-05 RU RU2009117170/15A patent/RU2443412C2/ru not_active IP Right Cessation
- 2007-10-05 EP EP07818736.6A patent/EP2086507B1/en not_active Not-in-force
- 2007-10-05 CA CA2664637A patent/CA2664637C/en not_active Expired - Fee Related
- 2007-10-05 CN CN2012104557068A patent/CN102940878A/zh active Pending
- 2007-10-05 PT PT78187358T patent/PT2081551E/pt unknown
- 2007-10-05 DK DK07818735.8T patent/DK2081551T3/da active
- 2007-10-05 JP JP2009530811A patent/JP5484059B2/ja not_active Expired - Fee Related
- 2007-10-05 ES ES07818736T patent/ES2708851T3/es active Active
- 2007-10-05 TW TW096137658A patent/TWI455731B/zh not_active IP Right Cessation
-
2009
- 2009-04-06 US US12/419,167 patent/US9526761B2/en not_active Expired - Fee Related
- 2009-04-06 US US12/419,131 patent/US20090297580A1/en not_active Abandoned
-
2013
- 2013-04-18 CY CY20131100316T patent/CY1113934T1/el unknown
-
2016
- 2016-03-08 US US15/064,444 patent/US20160220638A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120994T1 (el) | Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων | |
| CY1122617T1 (el) | Απαλλαγμενες prion συνθεσεις νανοσωματιδιων και μεθοδοι | |
| CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
| CY1113003T1 (el) | Ευσταθη παρασκευασματα laquinimod | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| PE20091964A1 (es) | Encapsulacion de agentes biologicamente activos | |
| CY1115838T1 (el) | Μεθοδος για τη σταθεροποιηση φαρμακοτεχνικων μορφων που περιεχουν μικροοργανισμους | |
| CY1112281T1 (el) | Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη | |
| CL2007002095A1 (es) | Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado. | |
| GT200600496A (es) | Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea. | |
| CY1119048T1 (el) | Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους | |
| ES2531173T3 (es) | Vehículos de administración de microemulsiones de lecitina a base de enlazadores | |
| CY1108306T1 (el) | Αναστολεις αζαϊνδολιου των mtp και apob | |
| CR10710A (es) | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas | |
| CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
| CY1118180T1 (el) | Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης | |
| ECSP099378A (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
| CY1108067T1 (el) | Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης | |
| CY1110812T1 (el) | Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων | |
| CY1113533T1 (el) | Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης | |
| CY1112185T1 (el) | Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη | |
| CY1117288T1 (el) | Παραγωγα 2-οξο-1-πυρρολιδινυλ ιμιδαζοθειαδιαζολης | |
| CR10124A (es) | Formulaciones orales que comprenden tigeciclina | |
| CY1116840T1 (el) | Χρηση 24-norudca |